Canada markets closed

Harvard Bioscience, Inc. (HBIO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.3000+0.0700 (+1.65%)
At close: 04:00PM EDT
4.3000 0.00 (0.00%)
After hours: 06:13PM EDT

Harvard Bioscience, Inc.

84 October Hill Road
Suite 10
Holliston, MA 01746
United States
508 893 8999

IndustryMedical Instruments & Supplies
Full Time Employees436

Key Executives

NameTitlePayExercisedYear Born
Mr. James W. GreenPres, CEO & Chairman607.35kN/A1958
Ms. Jennifer Cote CPA, CGMACFO & TreasurerN/AN/AN/A
Mr. David BalcomSr. VP of OperationsN/AN/AN/A
Mr. John J. FryChief Legal Counsel & Corp. Sec.N/AN/A1961
Mr. Ryan WallaceSr. VP of Global SalesN/AN/AN/A
Ms. Lori PackerVP of Global People OperationsN/AN/AN/A
David SiroisDirector of Corp. Accounting & SEC ReportingN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.

Corporate Governance

Harvard Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.